This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryder, N. S.
Right arrow Articles by Leitner, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryder, N. S.
Right arrow Articles by Leitner, I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1998, p. 1057-1061, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Activities of Terbinafine against Cutaneous Isolates of Candida albicans and Other Pathogenic Yeasts

Neil S. Ryder,* Sonja Wagner, and Ingrid Leitner

Novartis Research Institute, A-1235 Vienna, Austria

Received 22 January 1998/Returned for modification 17 February 1998/Accepted 9 March 1998

Terbinafine is active in vitro against a wide range of pathogenic fungi, including dermatophytes, molds, dimorphic fungi, and some yeasts, but earlier studies indicated that the drug had little activity against Candida albicans. In contrast, clinical studies have shown topical and oral terbinafine to be active in cutaneous candidiasis and Candida nail infections. In order to define the anti-Candida activity of terbinafine, we tested the drug against 350 fresh clinical isolates and additional strains by using a broth dilution assay standardized according to the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) M27-A assay. Terbinafine was found to have an MIC of 1 µg/ml for reference C. albicans strains. For 259 clinical isolates, the MIC at which 50% of the isolates are inhibited (MIC50) of terbinafine was 1 µg/ml (fluconazole, 0.5 µg/ml), and the MIC90 was 4 µg/ml (fluconazole, 1 µg/ml). Terbinafine was highly active against Candida parapsilosis (MIC90, 0.125 µg/ml) and showed potentially interesting activity against isolates of Candida dubliniensis, Candida guilliermondii, Candida humicola, and Candida lusitaniae. It was not active against the Candida glabrata, Candida krusei, and Candida tropicalis isolates in this assay. Cryptococcus laurentii and Cryptococcus neoformans were highly susceptible to terbinafine, with MICs of 0.06 to 0.25 µg/ml. The NCCLS macrodilution assay provides reproducible in vitro data for terbinafine against Candida and other yeasts. The MICs for C. albicans and C. parapsilosis are compatible with the known clinical efficacy of terbinafine in cutaneous infections, while the clinical relevance of its activities against the other species has yet to be determined.

* Corresponding author. Mailing address: Novartis Research Institute, Brunner Strasse 59, A-1235 Vienna, Austria. Phone: (431) 86634-324. Fax: (431) 86634-354. E-mail: neil.ryder{at}pharma.novartis.com.

Antimicrobial Agents and Chemotherapy, May 1998, p. 1057-1061, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Graminha, M. A. S., Rocha, E. M. F., Prade, R. A., Martinez-Rossi, N. M. (2004). Terbinafine Resistance Mediated by Salicylate 1-Monooxygenase in Aspergillus nidulans. Antimicrob. Agents Chemother. 48: 3530-3535 [Abstract] [Full Text]  
  • Smith, W. L., Edlind, T. D. (2002). Histone Deacetylase Inhibitors Enhance Candida albicans Sensitivity to Azoles and Related Antifungals: Correlation with Reduction in CDR and ERG Upregulation. Antimicrob. Agents Chemother. 46: 3532-3539 [Abstract] [Full Text]  
  • Perea, S., Gonzalez, G., Fothergill, A. W., Sutton, D. A., Rinaldi, M. G. (2002). In Vitro Activities of Terbinafine in Combination with Fluconazole, Itraconazole, Voriconazole, and Posaconazole against Clinical Isolates of Candida glabrata with Decreased Susceptibility to Azoles. J. Clin. Microbiol. 40: 1831-1833 [Abstract] [Full Text]  
  • Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Warnock, D. W. (2001). Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin. Microbiol. Rev. 14: 643-658 [Abstract] [Full Text]  
  • Moore, C. B., Walls, C. M., Denning, D. W. (2001). In Vitro Activities of Terbinafine against Aspergillus Species in Comparison with Those of Itraconazole and Amphotericin B. Antimicrob. Agents Chemother. 45: 1882-1885 [Abstract] [Full Text]  
  • Sugita, T., Takashima, M., Ikeda, R., Nakase, T., Shinoda, T. (2000). Intraspecies Diversity of Cryptococcus laurentii as Revealed by Sequences of Internal Transcribed Spacer Regions and 28S rRNA Gene and Taxonomic Position of C. laurentii Clinical Isolates. J. Clin. Microbiol. 38: 1468-1471 [Abstract] [Full Text]  
  • Favre, B., Didmon, M., Ryder, N. S. (1999). Multiple amino acid substitutions in lanosterol 14{alpha}-demethylase contribute to azole resistance in Candida albicans. Microbiology 145: 2715-2725 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»